论文部分内容阅读
作者以抗淋巴细胞血清(ALS)或抗胸腺细胞球蛋白(ATG)治疗22例再生障碍性贫血(AA)。大部分患者以往曾进行过雄激素和/或类固醇药物治疗。22例AA中19例为严重型。21例成人以15或22.5mlALS+5%葡萄糖水500ml静滴4-6小时,QD×14天。1名儿童以ALS 0.2ml/kg/日×14天。15例在ALS治疗期间加用氟羟甲雄酮(FOM),全部患者加用强的松30mg/日。在ALS或ATG输注过程中均使用了苯海拉明和扑热息痛。血清病者以抗组织胺、扑热息痛和强的松治疗。ALS或ATG输注前均经皮试。以ALS治疗者在治疗期每天做皮试,阳性反应者停止治疗。第1疗程中20例接受ALS,2例接受ATG治疗。其中7例有效(31.8%),4例完全缓
The authors treated 22 patients with aplastic anemia (AA) with anti-lymphocyte serum (ALS) or anti-thymocyte globulin (ATG). Most patients have had androgen and / or steroid treatment in the past. Twenty-nine cases of AA were severe. 21 adults with 15 or 22.5mlALS + 5% glucose water 500ml IV 4-6 hours, QD × 14 days. One child with ALS 0.2ml / kg / day × 14 days. Fifteen patients received Fomefuryone (FOM) during ALS and all patients received prednisone 30 mg daily. Diphenhydramine and paracetamol were used during ALS or ATG infusions. Serum patients with antihistamines, paracetamol and prednisone treatment. Transdermal test before ALS or ATG infusion. ALS treatment in patients with daily skin test, positive responders to stop treatment. Twenty patients underwent ALS in the first course of treatment and two received ATG. Seven of them were effective (31.8%) and four were completely relieved